Nutromics

About

Nutromics develops a Brunswick, Australia–based wearable diagnostic platform using DNA sensor patches for continuous, multi-target monitoring of drug levels and biomarkers, advancing in-human trials and integrated prototypes.

Mission

Nutromics is a Brunswick, Australia–based MedTech company developing a wearable diagnostic platform that uses DNA sensor technology to track multiple targets in the human body via a single patch. Its DNA sensors aim to provide continuous, real-time diagnostic information for clinicians and patients, including monitoring hard-to-dose drugs such as vancomycin and biomarkers for conditions like kidney disease. The company plans world-first in-human clinical studies of its first DNA sensors in 2022 and to complete an integrated alpha prototype device. Founded in 2017 by Peter Vranes (CEO) and Hitesh Mehta (COO), Nutromics is expanding its R&D and clinical programs. The recent US$14M funding will support expansion of clinical studies, growth of the R&D team, and investment across both Australian and U.S. hubs.

Quick Facts